TerminatedNCT03892889

A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®

Interventional studyAges 18–65United States

The study in practice

Understand this study

This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Listed locations: Phoenix and 67 more locationsSee all locations and recruitment

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateStarted: April 29, 2019

Recruitment status: Terminated
Enrollment listed in the registry: 277
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: COMBINATION_PRODUCT
Study phase: Phase 3
Locations: United States
Age range: From 18 Years to 65 Years
Official registry ID: NCT03892889
Official title: Show the full official title
A Phase IIIb Multi-Center, Open-Label, Mirror-Image, Trial in Adult Subjects With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®

Terminated

Phoenix · Little Rock · Anaheim

55 more locations

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Who can participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.